Don’t miss the latest developments in business and finance.

Cipla gets WHO approval for Q-TIB

Image
Capital Market
Last Updated : Nov 30 2017 | 4:31 PM IST

A novel fixed dose combination in a single tablet for TB prophylaxis in HIV

Cipla has received an approval for its product Q-TIB from World Health Organisation (WHO). Q-TIB is a novel fixed dose combination in a single tablet. This is the first time that such a combination has been made available in the world. Cipla will market the product globally. Q-TIB will help prevent tuberculosis infection in people living with HIV.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

More From This Section

First Published: Nov 30 2017 | 4:12 PM IST

Next Story